BioSpace News Archive

Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that its majority owned public entity, NuGenerex Immuno-Oncology, Inc. (NGIO), has filed for and expects to receive a trademark for The Complete Vaccine™

Buffalo Bills, 2020 AFC East Division Champions, and BioReference Laboratories, Inc., an OPKO Health company, announced they will be performing fan testing for the AFC Divisional Wild Card playoff game at Bills Stadium in Orchard Park.

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that interim safety and primary efficacy results from the Phase 3 trial of the Moderna COVID-19 Vaccine (mRNA-1273) were published in the New England Journal of Medicine.

Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today the launching of Campbell Neurosciences Inc as a partially owned spin-off from the Company.

An international collaboration of physicians has just published an updated protocol for early at-home treatment of COVID-19, which recognizes the three stages of the disease

EpiVax (“EpiVax”) and EpiVax Therapeutics (“EVT”) today provide an update on the advancement of their peptide-based COVID-19 vaccine, EPV-CoV-19.

Enveric Biosciences, Inc. announced the completion of the previously announced spin-off of the IT services business of the Company and the tender offer, whereby the Company purchased all of the outstanding common shares of Jay Pharma Inc. in exchange for shares of Company common stock, or if applicable, shares of Company preferred stock., and Jay Pharma became a wholly-owned subsidiary of the Company.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has signed a production agreement for both GLP and GMP materials associated with HT-001 with Tergus Pharma for its novel cancer treatment drug, HT-001.

MEDIROM Healthcare Technologies Inc. (NasdaqCM:MRM), a holistic healthcare company from Japan (the “Company”), announced today that it has closed its previously announced initial public offering of 800,000 ADSs at a price to the public of US$15.00 per share. Each ADS represents one share of the Company’s common stock.

Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnologies initiatives, today announced that it has been approved to be a Corporate Exhibitor at the 5th Annual CTIC Capital Pre-J.P. Morgan